Displaying archives for 2014 September:

Survey reveals emotional exhaustion affects many cancer specialists

Posted by Samantha Powell on September 30th, 2014 |

Across Europe, more than 70% of young cancer specialists are showing signs of burnout, the largest survey of its kind has revealed. The results, reported at the Congress of the European Society for Medical Oncology (ESMO 2014) in Madrid, have prompted calls for serious action to address the issue at all levels. “Oncology is an… Read More

Call Widens for Medicare CT Lung Cancer Screening Coverage

Posted by Samantha Powell on September 30th, 2014 |

More than 60 patient advocacy and medical organizations have joined a coalition headed by the Lung Cancer Alliance, the American College of Radiology and The Society of Thoracic Surgeons, in urging Medicare to cover low dose computed tomography (LDCT) screening for beneficiaries at high risk for lung cancer. In a new joint letter to the… Read More

How Not to Talk to Someone Dying of Cancer

Posted by Samantha Powell on September 29th, 2014 |

A friend of mine has been living well with lung cancer for five years — working, running several miles a day, traveling, doing good stuff with his family, and generally enjoying the pleasures of everyday life. He knows the cancer will eventually kill him, but has been making the most of every remaining minute. Then,… Read More

Bristol-Myers’ oncology star lines up for lung cancer approval, leading the PD-1 pack

Posted by Samantha Powell on September 29th, 2014 |

Among the scrum of drugmakers racing forward with a new class of cancer treatments, Bristol-Myers Squibb ($BMY) was the first to win a global regulatory nod and is now first in line for approval in lung cancer, a particularly lucrative indication for the group of promising oncology drugs. The company has completed a European application… Read More

CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer

Posted by Samantha Powell on September 29th, 2014 |

CytRx Corporation CYTR, -0.36% a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted multiple Orphan Drug Designations for the Company’s lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung cancer and ovarian cancer. Aldoxorubicin is CytRx’s modified version of… Read More

Data Confirm Anti-ALK Activity in Rare NSCLC

Posted by Samantha Powell on September 27th, 2014 |

Objective responses occurred in 72% of patients with mutation-specific non-small cell lung cancer (NSCLC) treated with crizotinib (Xalkori), final results from a small clinical trial showed. Median response duration approached 1½ years, and median progression-free survival (PFS) had reached 19.2 months with follow-up ongoing. All 50 patients enrolled in the study had chromosomal rearrangements in… Read More

Many patients excluded from clinical trials due to prior cancer, UTSW study finds

Posted by Samantha Powell on September 26th, 2014 |

Lung cancer clinical trials exclude a substantial proportion of patients due to a history of prior cancer, as shown in an analysis by cancer researchers at UT Southwestern Medical Center. Among more than 50 lung cancer clinical trials examined, more than 80 percent excluded patients with prior cancer from participating, according to the study published… Read More

Priceless Pills

Posted by Samantha Powell on September 26th, 2014 |

IN THE late 1800s a New York doctor noticed that getting an infection after surgery helped some cancer patients. So he began to treat cancer using infections and had a little success. But many doctors were sceptical of his work, and other treatments such as radiation therapy and chemotherapy eventually took off. Today, however, the… Read More

Conventional Surgery May Trump Radiosurgery for Some Early Lung Cancers

Posted by Samantha Powell on September 25th, 2014 |

Despite having a higher rate of early complications, patients with non-small cell lung cancer (NSCLC) did better in the long run with conventional surgery than with radiotherapy to remove their cancer, a finding that supports the current practice of treating healthier patients with surgery instead of radiosurgery. In this study from Yale University using Medicare… Read More

Stanford licenses promising cancer drug to local biotech startup

Posted by Samantha Powell on September 25th, 2014 |

Most cancer patients don’t die because of a single tumor, but rather multiple tumors that spread throughout the body. A new therapy, developed by Stanford University researchers and licensed by a local biotech startup, appears to disrupt the deadly process known as metastasis, which causes cancer cells to break away from the original tumor sites… Read More